Mental and Behavioral Health

Researchers analyzed overall prescription stimulant dispensing trends among US children from 2017 to 2023.

The approval makes Johnson and Johnson’s esketamine nasal spray the first and only monotherapy for the treatment of major depressive disorder in adult patients.

A conversation with Nina Vadiei, PharmD, BCPP, clinical associate professor in the Division of Pharmacotherapy at University of Texas at Austin College of Pharmacy and a clinical pharmacy specialist in psychiatry at the San Antonio State Hospital.

Nina Vadiei, PharmD, BCPP, discusses some of the challenges she faces working with forensic patients who have been charged with a crime and have severe mental illness.

A conversation with Kathleen Vest, PharmD, BCACP, CDCES, FCCP, professor of Pharmacy Practice at Drake University College of Pharmacy and Health Sciences.

Continued methylphenidate or atomoxetine use may be safe, but additional studies are needed.

The drug is also approved to treat schizophrenia and bipolar depression.

Researchers addressed the gut-first hypothesis of Parkinson disease by identifying how mucosal damage impacts risk of development.

Normalizing conversations around mental health in older adult populations can improve outcomes.

A conversation with Rakesh Jain, MD, MPH, clinical professor in the Department of Psychiatry at Texas Tech University School of Medicine.

Pharmacist management of chronic conditions can lead to improved patient outcomes.

The partnership will provide tools to address both patient and pharmacist well-being amid the current mental health crisis.

The COVID-19 pandemic negatively impacted mental health in young people, and additional targeted mental health resources are needed.

The once-daily, extended release, oral suspension medication was approved by the FDA in May 2024.

The approval of xanomeline and trospium chloride (Cobenfy) from Bristol Myers Squibb represents a “transformative moment in the treatment of schizophrenia.”

Study findings raise concern about increased pain and disability, poorer pain self-management, and impaired quality of life during adolescence that can continue into young adulthood.

Researchers conducted a meta-analysis and systematic review to determine the efficacy of using antidepressants to treat older adults for knee osteoarthritis pain.

Researchers conducted a meta-analysis detailing previous patient outcomes in response to visual art therapy interventions.

Researchers analyzed a co-developed pharmacy-based intervention for individuals who have experienced domestic abuse or suicidal ideation.

DaylightRX from Big Health is a digital formulation of cognitive behavioral therapy and is available by prescription only.

As research continues to uncover the potential benefits of psilocybin, pharmacists and other clinicians have an essential role in bridging ancient wisdom with contemporary science.

Rejoyn, developed by Otsuka Pharmaceutical and Click Therapeutics, is only accessible with a prescription from a health care provider.

The agency said it could not approve the new drug application based on the submitted data and requested an additional Phase 3 trial to “further study the safety and efficacy” of the therapy.

Sam Clark, MD, PhD, founder and CEO of Terran Biosciences, discusses the implications of a potential FDA approval of MDMA-assisted therapy for PTSD.

Researchers aimed to address the association of all-cause dementia risk and 3 separate chronicities of anxiety.